[EN] COMPOUNDS TARGETING MUTANT OF P53 [FR] COMPOSÉS CIBLANT UN MUTANT DE P53
摘要:
Provided are compounds of formula (I) which can bind to mutant p53 and restore the ability of the p53 mutant to bind DNA and activate downstream effectors involved in tumor suppression. Also provided are pharmaceutical compositions comprising the compounds, methods of preparing the compounds and the use in the manufacture of medicaments for preventing or treating a disease or condition related to p53 mutants.
[EN] DIARYLUREA DERIVATIVES AND THEIR USE AS CHLORIDE CHANNEL BLOCKERS [FR] DERIVES DE DIARYLUREE ET LEUR UTILISATION COMME BLOQUEURS DE CANAUX CHLORURE
Diarylurea derivatives and their use as chloride channel blockers
申请人:Dahl H Bjarne
公开号:US20060160856A1
公开(公告)日:2006-07-20
The present invention relates to novel diarylurea derivatives useful as chloride channel blockers. In other aspects the invention relates to the use of these compounds in a method for therapy, such as for the treatment of bone metabolic diseases, diseases responsive to modulation of the mast cell or basophil activity, diseases responsive to inhibition of angiogenesis, or sickle cell anaemia, and to pharmaceutical compositions comprising the compounds of the invention.
DIARYLUREA DERIVATIVES AND THEIR USE AS CHLORIDE CHANNEL BLOCKERS
申请人:NeuroSearch A/S
公开号:EP1537075B1
公开(公告)日:2009-07-01
[EN] DIARYLUREA DERIVATIVES AND THEIR USE AS CHLORIDE CHANNEL BLOCKERS<br/>[FR] DERIVES DE DIARYLUREE ET LEUR UTILISATION COMME BLOQUEURS DE CANAUX CHLORURE
申请人:NEUROSEARCH AS
公开号:WO2004022529A3
公开(公告)日:2004-05-13
[EN] COMPOUNDS TARGETING MUTANT OF P53<br/>[FR] COMPOSÉS CIBLANT UN MUTANT DE P53
申请人:[en]JACOBIO PHARMACEUTICALS CO., LTD.
公开号:WO2023016434A1
公开(公告)日:2023-02-16
Provided are compounds of formula (I) which can bind to mutant p53 and restore the ability of the p53 mutant to bind DNA and activate downstream effectors involved in tumor suppression. Also provided are pharmaceutical compositions comprising the compounds, methods of preparing the compounds and the use in the manufacture of medicaments for preventing or treating a disease or condition related to p53 mutants.